Lehmann L H, Fröhling S
Innere Medizin III, Abteilung für Kardiologie, Pneumologie und Angiologie, Sektion Kardio-Onkologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland.
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Standort Heidelberg/Mannheim, Heidelberg, Deutschland.
Internist (Berl). 2020 Nov;61(11):1132-1139. doi: 10.1007/s00108-020-00881-2.
Oncological therapies show a number of undesired adverse effects on the cardiovascular system. In particular, the side effects of recently established oncological therapies are incompletely understood and clinical data are lacking in the interpretation of novel cardiac complications.
This article provides a short overview of the mechanisms of cardiac side effects of certain oncological therapies.
The review is mainly based on data from preclinical studies.
Numerous toxic side effects have already been described and investigated in preclinical models. For certain groups of drugs (e.g. anthracyclines, tyrosine kinase inhibitors and immune checkpoint inhibitors) the underlying molecular mechanisms are still not fully understood.
An improved understanding of the molecular mechanism involved in cardiotoxicity might help improve the quality of clinical decisions. Additionally, it will provide new insights into the pathophysiology of cardiac diseases. The aim is to use the results of translational research and to clinically implement them in suitable cardio-oncology units.
肿瘤治疗对心血管系统有许多不良副作用。特别是，最近确立的肿瘤治疗的副作用尚未完全了解，且缺乏临床数据来解释新出现的心脏并发症。
本文简要概述了某些肿瘤治疗的心脏副作用机制。
本综述主要基于临床前研究数据。
在临床前模型中已经描述并研究了许多毒性副作用。对于某些药物组（如蒽环类药物、酪氨酸激酶抑制剂和免疫检查点抑制剂），其潜在的分子机制仍未完全了解。
更好地理解心脏毒性所涉及的分子机制可能有助于提高临床决策的质量。此外，它将为心脏病的病理生理学提供新的见解。目的是利用转化研究的结果并在合适的心脏肿瘤学单位将其临床应用。
